<DOC>
	<DOC>NCT02258529</DOC>
	<brief_summary>This study will evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in participants with follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) who have not received prior treatment.</brief_summary>
	<brief_title>Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirmed diagnosis of Bcell lymphoma No previous systemic treatment for lymphoma Subject demonstrates need for treatment for lymphoma AnnArbor Stage 2 (noncontiguous), 3, or 4 disease Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy Adequate performance status Required baseline laboratory data within protocolspecified parameters Known history of transformed lymphoma or diffuse large cell lymphoid malignancy Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment Known history of druginduced liver injury, chronic active hepatitis B (HBV), chronic active hepatitis C (HCV), alcoholic liver disease, nonalcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis Ongoing inflammatory bowel disease Known human immunodeficiency virus (HIV) infection History of prior allogeneic bone marrow progenitor cell or solid organ transplantation Ongoing immunosuppressive therapy, including systemic corticosteroids (&gt; 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Indolent Non-Hodgkin Lymphoma</keyword>
	<keyword>FL</keyword>
	<keyword>SLL</keyword>
</DOC>